Ibalizumab

Last Updated: 11/08/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 104 publications

HIV therapeutics in 2026.

HIV therapeutics in 2026.

Journal: Clinical microbiology reviews
Published: September 30, 2026

First virological control after >30 years of antiretroviral therapy in extensively drug-resistant HIV: potential role of lenacapavir plus ibalizumab.

First virological control after >30 years of antiretroviral therapy in extensively drug-resistant HIV: potential role of lenacapavir plus ibalizumab.

Journal: The Journal of antimicrobial chemotherapy
Published: September 11, 2026

Progress toward longer-acting antiretroviral regimens for adult HIV treatment.

Progress toward longer-acting antiretroviral regimens for adult HIV treatment.

Journal: Expert review of clinical pharmacology
Published: August 26, 2026

A precautionary tale of lenacapavir drug-drug interactions: A case series of two persons living with HIV receiving long-acting injections.

A precautionary tale of lenacapavir drug-drug interactions: A case series of two persons living with HIV receiving long-acting injections.

Journal: International journal of STD & AIDS
Published: June 18, 2026

People with HIV Continuing on Complex Regimens in the Era of Treatment Optimization: Characteristics and Outcomes.

People with HIV Continuing on Complex Regimens in the Era of Treatment Optimization: Characteristics and Outcomes.

Journal: AIDS patient care and STDs
Published: June 05, 2026

WG-am combinations restore antiviral potency against fostemsavir and lenacapavir-resistant HIV-1.

WG-am combinations restore antiviral potency against fostemsavir and lenacapavir-resistant HIV-1.

Journal: Antiviral research
Published: June 01, 2026

A French National Real-World Survey of People With Multiresistant HIV-1 Viruses Receiving an Antiretroviral Regimen Including Fostemsavir or Ibalizumab.

A French National Real-World Survey of People With Multiresistant HIV-1 Viruses Receiving an Antiretroviral Regimen Including Fostemsavir or Ibalizumab.

Journal: Open forum infectious diseases
Published: March 27, 2026

Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial.

Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial.

Journal: Nature medicine
Published: October 29, 2025

HIV-1 Non Group-M Phenotypic Susceptibility to Ibalizumab.

HIV-1 Non Group-M Phenotypic Susceptibility to Ibalizumab.

Journal: Journal of medical virology
Published: September 02, 2025

Combined Use of Ibalizumab and Lenacapavir for the Treatment of Multidrug-resistant HIV-1: A Case Series.

Combined Use of Ibalizumab and Lenacapavir for the Treatment of Multidrug-resistant HIV-1: A Case Series.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: June 23, 2025

Switch from Ibalizumab to Lenacapavir in a Rescue Regimen for a Heavily Treatment-Experienced (HTE) Patient with Multidrug-Resistant (MDR) HIV-1 Infection.

Switch from Ibalizumab to Lenacapavir in a Rescue Regimen for a Heavily Treatment-Experienced (HTE) Patient with Multidrug-Resistant (MDR) HIV-1 Infection.

Journal: International journal of molecular sciences
Published: June 12, 2025

Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with multidrug resistant HIV-1: A phase 3, multicenter, expanded access study.

Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with multidrug resistant HIV-1: A phase 3, multicenter, expanded access study.

Journal: Journal of acquired immune deficiency syndromes (1999)
Published: June 04, 2025
Showing 1-12 of 104

Last Updated: 11/08/2026